Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment
Tóm tắt
The currently available techniques for the safety evaluation of candidate drugs are usually cost-intensive and time-consuming and are often insufficient to predict human relevant cardiotoxicity. The purpose of this study was to develop an in vitro repeated exposure toxicity methodology allowing the identification of predictive genomics biomarkers of functional relevance for drug-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). The hiPSC-CMs were incubated with 156 nM doxorubicin, which is a well-characterized cardiotoxicant, for 2 or 6 days followed by washout of the test compound and further incubation in compound-free culture medium until day 14 after the onset of exposure. An xCELLigence Real-Time Cell Analyser was used to monitor doxorubicin-induced cytotoxicity while also monitoring functional alterations of cardiomyocytes by counting of the beating frequency of cardiomyocytes. Unlike single exposure, repeated doxorubicin exposure resulted in long-term arrhythmic beating in hiPSC-CMs accompanied by significant cytotoxicity. Global gene expression changes were studied using microarrays and bioinformatics tools. Analysis of the transcriptomic data revealed early expression signatures of genes involved in formation of sarcomeric structures, regulation of ion homeostasis and induction of apoptosis. Eighty-four significantly deregulated genes related to cardiac functions, stress and apoptosis were validated using real-time PCR. The expression of the 84 genes was further studied by real-time PCR in hiPSC-CMs incubated with daunorubicin and mitoxantrone, further anthracycline family members that are also known to induce cardiotoxicity. A panel of 35 genes was deregulated by all three anthracycline family members and can therefore be expected to predict the cardiotoxicity of compounds acting by similar mechanisms as doxorubicin, daunorubicin or mitoxantrone. The identified gene panel can be applied in the safety assessment of novel drug candidates as well as available therapeutics to identify compounds that may cause cardiotoxicity.
Tài liệu tham khảo
Akhmedov AT, Rybin V, Marin-Garcia J (2015) Mitochondrial oxidative metabolism and uncoupling proteins in the failing heart. Heart Fail Rev 20:227–249
Anson BD, Kolaja KL, Kamp TJ (2011) Opportunities for use of human iPS cells in predictive toxicology. Clin Pharmacol Ther 89:754–758
Appel JM, Nielsen D, Zerahn B, Jensen BV, Skagen K (2007) Anthracycline-induced chronic cardiotoxicity and heart failure. Acta Oncol 46:576–580
Babuin L, Jaffe AS (2005) Troponin: the biomarker of choice for the detection of cardiac injury. CMAJ 173:1191–1202
Boucek RJ, Dodd DA, Atkinson JB, Oquist N, Olson RD (1997) Contractile failure in chronic doxorubicin-induced cardiomyopathy. J Mol Cell Cardiol 29:2631–2640
Braunlin EA, Wahler GM, Swayze CR, Lucas RV, Fox IJ (1986) Myoglobin facilitated oxygen diffusion maintains mechanical function of mammalian cardiac-muscle. Cardiovasc Res 20:627–636
Bugger H, Guzman C, Zechner C, Palmeri M, Russell KS, Russell RR (2011) Uncoupling protein downregulation in doxorubicin-induced heart failure improves mitochondrial coupling but increases reactive oxygen species generation. Cancer Chemother Pharmacol 67:1381–1388
Caspi O, Itzhaki I, Kehat I, Gepstein A, Arbel G, Huber I, Satin J, Gepstein L (2009) In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes. Stem Cells Dev 18:161–172
Chandran K, Aggarwal D, Migrino RQ, Joseph J, McAllister D, Konorev EA, Antholine WE, Zielonka J, Srinivasan S, Avadhani NG, Kalyanaraman B (2009) Doxorubicin inactivates myocardial cytochrome c oxidase in rats: cardioprotection by Mito-Q. Biophys J 96:1388–1398
Communal C, Colucci WS, Remondino A, Sawyer DB, Port JD, Wichman SE, Bristow MR, Singh K (2002) Reciprocal modulation of mitogen-activated protein kinases and mitogen-activated protein kinase phosphatase 1 and 2 in failing human myocardium. J Card Fail 8:86–92
Dennis G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA (2003) DAVID: database for annotation, visualization, and integrated discovery. Genome Biol 4:R60
Dindogru A, Barcos M, Henderson ES, Wallace HJ (1978) Electrocardiographic changes following adriamycin treatment. Med Pediatr Oncol 5:65–71
Dodd DA, Atkinson JB, Olson RD, Buck S, Cusack BJ, Fleischer S, Boucek RJ (1993) Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of the sarcoplasmic-reticulum in a chronic rabbit model. J Clin Invest 91:1697–1705
Eiken HG, Oie E, Damas JK, Yndestad A, Bjerkeli V, Aass H, Simonsen S, Geiran OR, Tonnessen T, Christensen G, Froland SS, Gullestad L, Attramadal H, Aukrust P (2001) Myocardial gene expression of leukaemia inhibitory factor, interleukin-6 and glycoprotein 130 in end-stage human heart failure. Eur J Clin Invest 31:389–397
Eisen MB, Spellman PT, Brown PO, Botstein D (1999) Cluster analysis and display of genome-wide expression patterns (vol 95, pg 14863, 1998). Proc Natl Acad Sci USA 96:10943
Friess GG, Boyd JF, Geer MR, Garcia JC (1985) Effects of 1st-dose doxorubicin on cardiac-rhythm as evaluated by continuous 24-hour monitoring. Cancer 56:2762–2764
Gautier L, Cope L, Bolstad BM, Irizarry RA (2004) affy—analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20:307–315
Gewirtz D (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57:727–741
Go LO, Moschella MC, Watras J, Handa KK, Fyfe BS, Marks AR (1995) Differential regulation of 2 types of intracellular calcium-release channels during end-stage heart-failure. J Clin Invest 95:888–894
Goulter AB, Goddard MJ, Allen JC, Clark KL (2004) ACE2 gene expression is up-regulated in the human failing heart. BMC Med 2:19
Haq MM, Legha SS, Choksi J, Hortobagyi GN, Benjamin RS, Ewer M, Ali M (1985) Doxorubicin-induced congestive heart-failure in adults. Cancer 56:1361–1365
He JQ, Ma Y, Lee Y, Thomson JA, Kamp TJ (2003) Human embryonic stem cells develop into multiple types of cardiac myocytes—action potential characterization. Circ Res 93:32–39
Hsiao EC, Koniaris LG, Zimmers-Koniaris T, Sebald SM, Huynh TV, Lee SJ (2000) Characterization of growth-differentiation factor 15, a transforming growth factor beta superfamily member induced following liver injury. Mol Cell Biol 20:3742–3751
Ibrahim NK, Hortobagyi GN, Ewer M, Ali MK, Asmar L, Theriault RL, Fraschini G, Frye DK, Buzdar AU (1999) Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience. Cancer Chemother Pharmacol 43:471–478
Kehoe R, Singer DH, Trapani A, Billingham M, Levandowski R, Elson J (1978) Adriamycin-induced cardiac dysrhythmias in an experimental dog model. Cancer Treat Rep 62:963–978
Kempf T, Wollert KC (2009) Growth differentiation factor-15: a new biomarker in cardiovascular disease. Herz 34:594–599
Khan SQ, Ng K, Dhillon O, Kelly D, Quinn P, Squire IB, Davies JE, Ng LL (2009) Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction. Eur Heart J 30:1057–1065
Lacasse Y, Bolduc P (1992) Sudden-death in leukemic patients treated with doxorubicin. Can J Cardiol 8:53–56
Latif N, Khan MA, Birks E, O’Farrell A, Westbrook J, Dunn MJ, Yacoub MH (2000) Upregulation of the Bcl-2 family of proteins in end stage heart failure. J Am Coll Cardiol 35:1769–1777
Lofgren C, Lehmann S, Jonsson-Videsater K, Mollgard L, Linder O, Tidefelt U, Hassan M, Paul C (2007) Higher plasma but not intracellular concentrations after infusion with liposomal daunorubicin compared with conventional daunorubicin in adult acute myeloid leukemia. Ther Drug Monit 29:626–631
Menna P, Paz OG, Chello M, Covino E, Salvatorelli E, Minotti G (2012) Anthracycline cardiotoxicity. Expert Opin Drug Saf 11(Suppl 1):S21–S36
Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185–229
Nabauer M, Kaab S (1998) Potassium channel down-regulation in heart failure. Cardiovasc Res 37:324–334
Nascimben L, Ingwall JS, Pauletto P, Friedrich J, Gwathmey JK, Saks V, Pessina AC, Allen PD (1996) Creatine kinase system in failing and nonfailing human myocardium. Circulation 94:1894–1901
O’Brien PJ (2008) Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity. Toxicology 245:206–218
Obrien PJ, Ogrady M, Mccutcheon LJ, Shen H, Nowack L, Horne RD, Mirsalimi SM, Julian RJ, Grima EA, Moe GW, Armstrong PW (1992) Myocardial myoglobin deficiency in various animal-models of congestive-heart-failure. J Mol Cell Cardiol 24:721–730
Paul F, Dorr J, Wurfel J, Vogel HP, Zipp F (2007) Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 78:198–200
Remme CA, Bezzina CR (2010) Sodium channel (dys)function and cardiac arrhythmias. Cardiovasc Ther 28:287–294
Reppel M, Pillekamp F, Brockmeier K, Matzkies M, Bekcioglu A, Lipke T, Nguemo F, Bonnemeier H, Hescheler J (2005) The electrocardiogram of human embryonic stem cell-derived cardiomyocytes. J Electrocardiol 38:166–170
Safran M, Dalah I, Alexander J, Rosen N, Stein TI, Shmoish M, Nativ N, Bahir I, Doniger T, Krug H, Sirota-Madi A, Olender T, Golan Y, Stelzer G, Harel A, Lancet D (2010) GeneCards version 3: the human gene integrator. Database (Oxford) 2010:baq020. doi:10.1093/database/baq020
Sawyer DB, Zuppinger C, Miller TA, Eppenberger HM, Suter TM (2002) Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1 beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 105:1551–1554
Sheppard R, Bedi M, Kubota T, Semigran MJ, Dec W, Holubkov R, Feldman AM, Rosenblum WD, McTiernan CF, McNamara DM (2005) Myocardial expression of Fas and recovery of left ventricular function in patients with recent-onset cardiomyopathy. J Am Coll Cardiol 46:1036–1042
Srinivasan S, Avadhani NG (2012) Cytochrome c oxidase dysfunction in oxidative stress. Free Radic Biol Med 53:1252–1263
Steel D, Hyllner J, Sartipy P (2009) Cardiomyocytes derived from human embryonic stem cells—characteristics and utility for drug discovery. Curr Opin Drug Discov Devel 12:133–140
Sundman-Engberg B, Tidefelt U, Gruber A, Paul C (1993) Intracellular concentrations of mitoxantrone in leukemic cells in vitro vs in vivo. Leuk Res 17:347–352
Sussman MA, HammAlvarez SF, Vilalta PM, Welch S, Kedes L (1997) Involvement of phosphorylation in doxorubicin-mediated myofibril degeneration—an immunofluorescence microscopy analysis. Circ Res 80:52–61
Szuts V, Menesi D, Varga-Orvos Z, Zvara A, Houshmand N, Bitay M, Bogats G, Virag L, Baczko I, Szalontai B, Geramipoor A, Cotella D, Wettwer E, Ravens U, Deak F, Puskas LG, Papp JG, Kiss I, Varro A, Jost N (2013) Altered expression of genes for Kir ion channels in dilated cardiomyopathy. Can J Physiol Pharmacol 91:648–656
Tafuri G, Trotta F, Leufkens HGM, Pani L (2013) Disclosure of grounds of European withdrawn and refused applications: a step forward on regulatory transparency. Br J Clin Pharmacol 75:1149–1151
Tonomura Y, Mori Y, Torii M, Uehara T (2009) Evaluation of the usefulness of biomarkers for cardiac and skeletal myotoxicity in rats. Toxicology 266:48–54
Wang FF, Guo YH, Yu HY, Zheng LB, Mi L, Gao W (2010) Growth differentiation factor 15 in different stages of heart failure: potential screening implications. Biomarkers 15:671–676
Yan XH, Morgan JP (2011) Neuregulin1 as novel therapy for heart failure. Curr Pharm Des 17:1808–1817
Zimmers TA, Jim XL, Hsiao EC, McGrath SA, Esquela AF, Koniaris LG (2005) Growth differentiation factor-15/macrophage inhibitory cytokine-1 induction after kidney and lung injury. Shock 23:543–548